Alumis(ALMS)
SOUTH SAN FRANCISCO, CA
BiotechnologyFocus: Autoimmune Treatments
Alumis is a life sciences company focused on Autoimmune Treatments.
Immunology
Funding Stage
PUBLIC
Open Jobs
12
Pipeline & Clinical Trials
ESK-001
PharmacokineticsClinical Trials (1)
NCT05330858Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants
Phase 1Experimental drug: ESK-001
Safety and TolerabilityClinical Trials (1)
NCT05431634Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants
Phase 1ESK-001
Healthy VolunteerClinical Trials (1)
NCT07378579An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001
Phase 1ESK-001
Hepatic ImpairmentClinical Trials (1)
NCT06952634An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage
Phase 1A-005
Healthy VolunteerClinical Trials (1)
NCT07442149An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005
Phase 1ESK-001
Renal ImpairmentClinical Trials (1)
NCT06962774An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function
Phase 1ESK-001
SLEClinical Trials (1)
NCT05966480Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
Phase 2ESK-001
Plaque PsoriasisClinical Trials (1)
NCT05600036A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis
Phase 2ESK-001
Plaque PsoriasisClinical Trials (1)
NCT05739435Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
Phase 2Phase 2
Clinical Trials (1)
NCT05953688POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU
Phase 2Open-Label ESK-001
Plaque PsoriasisClinical Trials (1)
NCT06846541Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
Phase 3ESK-001
Plaque PsoriasisClinical Trials (1)
NCT06586112A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
Phase 3ESK-001
Plaque PsoriasisClinical Trials (1)
NCT06588738A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
Phase 3Open Jobs (12)
Director Clinical Pharmacology & DMPK
South San Francisco
Supply Chain5d ago
From $200K/yr
Director, GCP Compliance
South San Francisco
Clinical Operations1w ago
From $201K/yr
Regional Director of MSLs
United States
Medical Affairs1w ago
$22K - $250K/yr
Data Systems & Clinical Programming Specialist (Contractor)
South San Francisco
633 Biometrics2w ago
Senior Manager, Statistical Programming
South San Francisco
633 Biometrics1mo ago
$180K - $21K/yr
Senior Manager, Pharmacovigilance Safety Operations
South San Francisco
634 Pharmacovigilance1mo ago
Senior Manager, IT, R&D Applications (Contractor)
South San Francisco
IT1mo ago
$168K - $200K/yr
Vice President Corporate Communications & Investor Relations
South San Francisco
Finance1mo ago
From $285K/yr
Vice President, Medical Affairs
South San Francisco
Medical Affairs1mo ago
From $315K/yr
Associate Director, Biostatistics
South San Francisco
Clinical Development3mo ago
Senior Medical Director, Rheumatology
South San Francisco
631 Clinical Science3mo ago
From $300K/yr
Senior Clinical Development (Medical Director), Dermatology
South San Francisco
631 Clinical Science10mo ago
From $325K/yr
Interview Prep Quick Facts
Founded: 2010
Portfolio: 13 clinical trials
Top TAs: Immunology, Gastroenterology, Nephrology
SEC Filings: 1 available
Open Roles: 12 active jobs
Therapeutic Area Focus
Marketed
Pipeline
Hiring Trend
Stable
12
Open Roles
+2
Added
-0
Filled/Removed
Based on last 4 crawl cycles